Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
American Heart Association (20POST35210923)
U.S. Department of Health & Human Services | National Institutes of Health (F32 DK117568, R01HL137365, R01HL135090)
National Science Foundation (CMMI: 15-48571)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 25 May 2020
Accepted: 7 January 2021
First Online: 2 February 2021
Competing interests
: J.A.B. owns equity in Prolifagen, a start-up company exploring miRNA therapeutics for cardiac repair. The remaining authors declare no competing interests.
